Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.

IF 2.2 4区医学 Q3 BIOCHEMICAL RESEARCH METHODS Molecular Imaging Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI:10.1177/15353508241261473

Linhan Zhang, Lianmeng Zhao, Xue Lin, Sheng Zhao, Wenbin Pan, Dandan Wang, Zhongqi Sun, Jinping Li, Zonghui Liang, Rongjun Zhang, Huijie Jiang

{"title":"Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.","authors":"Linhan Zhang, Lianmeng Zhao, Xue Lin, Sheng Zhao, Wenbin Pan, Dandan Wang, Zhongqi Sun, Jinping Li, Zonghui Liang, Rongjun Zhang, Huijie Jiang","doi":"10.1177/15353508241261473","DOIUrl":null,"url":null,"abstract":"Background: Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases.Objectives: To explore factors affecting labeled antibody visualization by PD-L1 specific and non-specific imaging of nude mouse tumors.Methods: TTU was observed in RKO model on Cerenkov luminescence (CL) and near-infrared fluorescence (NIRF) imaging of radionuclide 131I or NIRF dyes labeled Atezolizumab and IgG. A mixture of NIRF dyes labeled Atezolizumab and 131I-labeled IgG was injected, and TTU was observed in the RKO and HCT8 model by NIRF/CL dual-modality in-situ imaging. TTU were observed by 131I-labeled Atezolizumab and IgG in-vitro distribution.Results: Labeled IgG concentrated more in tumors than Atezolizumab. NIRF/CL imaging in 24 to 168 h showed that TTU gradually decreased over time, which decreased more slowly on CL imaging compared to NIRF imaging. The distribution data in-vitro showed that TTU of 131I-labeled IgG was higher than that of 131I-labeled Atezolizumab at any time point.Conclusion: Non-specific IgG may not be suitable as a control for Atezolizumab in comparing tumor PD-L1 expression in nude mice via labeled antibody optical imaging under certain circumstances.","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"23 ","pages":"15353508241261473"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208884/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15353508241261473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases.

Objectives: To explore factors affecting labeled antibody visualization by PD-L1 specific and non-specific imaging of nude mouse tumors.

Methods: TTU was observed in RKO model on Cerenkov luminescence (CL) and near-infrared fluorescence (NIRF) imaging of radionuclide ¹³¹I or NIRF dyes labeled Atezolizumab and IgG. A mixture of NIRF dyes labeled Atezolizumab and ¹³¹I-labeled IgG was injected, and TTU was observed in the RKO and HCT8 model by NIRF/CL dual-modality in-situ imaging. TTU were observed by ¹³¹I-labeled Atezolizumab and IgG in-vitro distribution.

Results: Labeled IgG concentrated more in tumors than Atezolizumab. NIRF/CL imaging in 24 to 168 h showed that TTU gradually decreased over time, which decreased more slowly on CL imaging compared to NIRF imaging. The distribution data in-vitro showed that TTU of ¹³¹I-labeled IgG was higher than that of ¹³¹I-labeled Atezolizumab at any time point.

Conclusion: Non-specific IgG may not be suitable as a control for Atezolizumab in comparing tumor PD-L1 expression in nude mice via labeled antibody optical imaging under certain circumstances.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

近红外荧光/切尔诺科夫荧光双模态原位成像对肿瘤非特异性和 PD-L1 特异性成像的比较

背景：标记抗体是肿瘤学中极佳的成像剂，可无创地观察癌症相关抗原的表达水平。然而，在某些情况下，体内特异性抗体的肿瘤示踪吸收（TTU）可能不如非特异性 IgG：探索影响裸鼠肿瘤 PD-L1 特异性和非特异性成像标记抗体可视化的因素：方法：在 RKO 模型中，用放射性核素 131I 或 NIRF 染料标记 Atezolizumab 和 IgG，通过 Cerenkov 发光（CL）和近红外荧光（NIRF）成像观察 TTU。注射 NIRF 染料标记的 Atezolizumab 和 131I 标记的 IgG 的混合物，通过 NIRF/CL 双模式原位成像在 RKO 和 HCT8 模型中观察 TTU。通过 131I 标记的 Atezolizumab 和 IgG 的体外分布观察 TTU：结果：标记的 IgG 比 Atezolizumab 更集中在肿瘤中。24 至 168 h 的 NIRF/CL 成像显示，随着时间的推移，TTU 逐渐下降，与 NIRF 成像相比，CL 成像的下降速度更慢。体外分布数据显示，在任何时间点，131I 标记的 IgG 的 TTU 都高于 131I 标记的阿特珠单抗：结论：在某些情况下，通过标记抗体光学成像比较裸鼠肿瘤 PD-L1 表达时，非特异性 IgG 可能不适合作为 Atezolizumab 的对照。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Molecular Imaging Biochemistry, Genetics and Molecular Biology-Biotechnology

自引率

3.60%

发文量

期刊介绍： Molecular Imaging is a peer-reviewed, open access journal highlighting the breadth of molecular imaging research from basic science to preclinical studies to human applications. This serves both the scientific and clinical communities by disseminating novel results and concepts relevant to the biological study of normal and disease processes in both basic and translational studies ranging from mice to humans.